Table 1 Patient characteristics at baseline (week 0)*
|  | Total (n = 84) | CZP + MTX (n = 41) | CZP (n = 43) |
|---|---|---|---|
Age, years | 59.2 ± 15.1 | 60.2 ± 14.2 | 58.2 ± 15.9 |
Female, no. (%) | 70 (83.3) | 35 (85.4) | 35 (81.4) |
Height, cm | 158.2 ± 7.5 | 158.3 ± 6.8 | 158.2 ± 8.3 |
Weight, kg | 54.6 ± 10.2 | 53.4 ± 8.5 | 55.7 ± 11.6 |
Disease duration, years | 10.2 ± 7.6 | 11.7 ± 9.2 | 8.7 ± 5.4 |
RF positivity, no. (%) | 83 (98.8) | 40 (97.6) | 43 (100) |
ACPA positivity, no. (%) | 63 (75.0) | 28 (68.3) | 35 (81.4) |
Previous use of b/tsDMARDs, no. (%) | 41 (48.8) | 22 (53.7) | 19 (44.2) |
Duration of treatment with CZP, years | 3.8 ± 2.1 | 3.4 ± 1.7 | 4.1 ± 2.4 |
MTX dose, mg/week | 8.3 ± 2.4 | 7.9 ± 2.0 | 8.7 ± 2.6 |
Use of glucocorticoids, no. (%) | 2 (2.4) | 2 (4.9) | 0 (0) |
Use of csDMARDs other than MTX, no. (%) | 20 (23.8) | 7 (17.1) | 13 (30.2) |
28 TJC | 0.4 ± 0.8 | 0.6 ± 1.0 | 0.3 ± 0.6 |
28 SJC | 0.5 ± 1.0 | 0.7 ± 1.3 | 0.3 ± 0.7 |
PtGA, 0–100 mm scale | 10.4 ± 14.1 | 10.6 ± 14.5 | 10.2 ± 13.9 |
PhGA, 0–100 mm scale | 6.1 ± 6.2 | 5.8 ± 5.0 | 6.4 ± 7.2 |
CRP, mg/dL†| 0.14 ± 0.57 | 0.07 ± 0.08 | 0.20 ± 0.79 |
MMP-3, ng/mL | 48.8 ± 33.3 | 51.6 ± 45.3 | 46.2 ± 17.1 |
CDAI | 2.6 ± 2.6 | 2.9 ± 2.9 | 2.3 ± 2.3 |
HAQ-DI | 0.3 ± 0.5 | 0.3 ± 0.5 | 0.3 ± 0.5 |
EQ-5D | 0.861 ± 0.149 | 0.862 ± 0.156 | 0.860 ± 0.145 |